Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Decreased recognition of paraneoplastic pemphigus in patients previously treated with anti-CD 20 monoclonal antibodies.

Kwatra SG, Boozalis E, Pasieka H, Anhalt GJ.

Br J Dermatol. 2019 May;180(5):1238-1239. doi: 10.1111/bjd.17577. Epub 2019 Jan 15. No abstract available.

PMID:
30648258
2.

The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis.

Atzmony L, Hodak E, Leshem YA, Rosenbaum O, Gdalevich M, Anhalt GJ, Mimouni D.

J Am Acad Dermatol. 2015 Aug;73(2):264-71. doi: 10.1016/j.jaad.2015.04.038. Epub 2015 Jun 16. Review.

PMID:
26088689
3.

Mucosal pemphigus vulgaris anti-Dsg3 IgG is pathogenic to the oral mucosa of humanized Dsg3 mice.

Culton DA, McCray SK, Park M, Roberts JC, Li N, Zedek DC, Anhalt GJ, Cowley DO, Liu Z, Diaz LA.

J Invest Dermatol. 2015 Jun;135(6):1590-1597. doi: 10.1038/jid.2015.54. Epub 2015 Feb 19.

4.

Pemphigus vulgaris autoantibody profiling by proteomic technique.

Kalantari-Dehaghi M, Anhalt GJ, Camilleri MJ, Chernyavsky AI, Chun S, Felgner PL, Jasinskas A, Leiferman KM, Liang L, Marchenko S, Nakajima-Sasaki R, Pittelkow MR, Zone JJ, Grando SA.

PLoS One. 2013;8(3):e57587. doi: 10.1371/journal.pone.0057587. Epub 2013 Mar 7.

5.

Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients.

Leshem YA, Hodak E, David M, Anhalt GJ, Mimouni D.

J Am Acad Dermatol. 2013 Mar;68(3):404-11. doi: 10.1016/j.jaad.2012.08.010. Epub 2012 Oct 6.

PMID:
23044076
6.

Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris.

Mimouni D, Blank M, Payne AS, Anhalt GJ, Avivi C, Barshack I, David M, Shoenfeld Y.

Clin Exp Immunol. 2010 Dec;162(3):543-9. doi: 10.1111/j.1365-2249.2010.04265.x. Epub 2010 Oct 21.

7.

Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial.

Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ.

J Invest Dermatol. 2010 Aug;130(8):2041-8. doi: 10.1038/jid.2010.91. Epub 2010 Apr 22.

8.

Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy.

Thorne JE, Woreta FA, Jabs DA, Anhalt GJ.

Ophthalmology. 2008 Dec;115(12):2146-2152.e1. doi: 10.1016/j.ophtha.2008.08.002. Epub 2008 Oct 18.

PMID:
18930554
9.

Transformation of cutaneous gamma/delta T-cell lymphoma following 15 years of indolent behavior.

Hosler GA, Liégeois N, Anhalt GJ, Moresi JM.

J Cutan Pathol. 2008 Nov;35(11):1063-7. doi: 10.1111/j.1600-0560.2007.00931.x. Epub 2008 Jun 9.

PMID:
18544066
10.

Rituximab therapy in severe juvenile pemphigus vulgaris.

Mamelak AJ, Eid MP, Cohen BA, Anhalt GJ.

Cutis. 2007 Oct;80(4):335-40.

PMID:
18038698
11.

Treatment of pyoderma gangrenosum with intravenous immunoglobulin.

Cummins DL, Anhalt GJ, Monahan T, Meyerle JH.

Br J Dermatol. 2007 Dec;157(6):1235-9. Epub 2007 Oct 4. Review.

PMID:
17916196
12.

Adalimumab therapy for recalcitrant pyoderma gangrenosum.

Fonder MA, Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH.

J Burns Wounds. 2006 Nov 20;5:e8.

13.

Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies.

Cummins DL, Mimouni D, Tzu J, Owens N, Anhalt GJ, Meyerle JH.

J Am Acad Dermatol. 2007 Jan;56(1):153-9. Epub 2006 Sep 14.

PMID:
17097371
14.

Bullous pemphigoid in a patient with systemic sclerosis (scleroderma).

Sherber NS, Wigley FM, Anhalt GJ.

J Rheumatol. 2006 Oct;33(10):2098. No abstract available.

PMID:
17014027
15.

Role of electron microscopy in the diagnosis of ocular mucous membrane pemphigoid.

Thorne JE, Anhalt GJ, Jabs DA, de la Cruz Z, Green WR.

Ophthalmology. 2006 Sep;113(9):1651-6. Epub 2006 Jul 7.

PMID:
16828515
16.

Pernicious anemia and widespread absence of gastrointestinal endocrine cells in a patient with autoimmune polyglandular syndrome type I and malabsorption.

Oliva-Hemker M, Berkenblit GV, Anhalt GJ, Yardley JH.

J Clin Endocrinol Metab. 2006 Aug;91(8):2833-8. Epub 2006 May 9.

PMID:
16684833
17.

Childhood IgA-mediated epidermolysis bullosa acquisita responding to mycophenolate mofetil as a corticosteroid-sparing agent.

Tran MM, Anhalt GJ, Barrett T, Cohen BA.

J Am Acad Dermatol. 2006 Apr;54(4):734-6. No abstract available.

PMID:
16546607
18.

Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.

Mimouni D, Blank M, Ashkenazi L, Milner Y, Frusic-Zlotkin M, Anhalt GJ, David M, Shoenfeld Y.

Clin Exp Immunol. 2005 Dec;142(3):426-32.

19.

Mucous membrane pemphigoid of the vulva.

Goldstein AT, Anhalt GJ, Klingman D, Burrows LJ.

Obstet Gynecol. 2005 May;105(5 Pt 2):1188-90.

PMID:
15863576
20.

Paraneoplastic pemphigus in a dog with splenic sarcoma.

Elmore SA, Basseches J, Anhalt GJ, Cullen JM, Olivry T.

Vet Pathol. 2005 Jan;42(1):88-91.

PMID:
15657279
21.

Mucosal dominant pemphigus vulgaris with anti-desmoplakin autoantibodies.

Mimouni D, Foedinger D, Kouba DJ, Orlow SJ, Rappersberger K, Sciubba JJ, Nikolskaia OV, Cohen BA, Anhalt GJ, Nousari CH.

J Am Acad Dermatol. 2004 Jul;51(1):62-7.

PMID:
15243525
22.

Pemphigus vulgaris--a model for cutaneous autoimmunity.

Anhalt GJ, Díaz LA.

J Am Acad Dermatol. 2004 Jul;51(1 Suppl):S20-1. Review. No abstract available.

PMID:
15243495
23.

Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations.

Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S.

Oral Oncol. 2004 Jul;40(6):553-62. Review.

PMID:
15063382
24.

Paraneoplastic pemphigus.

Anhalt GJ.

J Investig Dermatol Symp Proc. 2004 Jan;9(1):29-33. Review. No abstract available.

25.

Mucous membrane pemphigoid and pseudopemphigoid.

Thorne JE, Anhalt GJ, Jabs DA.

Ophthalmology. 2004 Jan;111(1):45-52.

PMID:
14711713
26.

Paraneoplastic pemphigus in association with Castleman's disease.

Nikolskaia OV, Nousari CH, Anhalt GJ.

Br J Dermatol. 2003 Dec;149(6):1143-51.

PMID:
14674890
27.

Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris.

Mimouni D, Nousari CH, Cummins DL, Kouba DJ, David M, Anhalt GJ.

J Am Acad Dermatol. 2003 Dec;49(6):1059-62.

PMID:
14639384
28.

Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus.

Schadlow MB, Anhalt GJ, Sinha AA.

J Drugs Dermatol. 2003 Oct;2(5):564-7.

PMID:
14558407
29.

Vesicular pemphigoid in a 16-year-old boy.

Geyer AS, Zillikens D, Skrobek C, Cohen B, Anhalt GJ, Nousari HC.

J Am Acad Dermatol. 2003 Oct;49(4):722-4.

PMID:
14512926
30.

Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus.

Cummins DL, Mimouni D, Anhalt GJ, Nousari CH.

J Am Acad Dermatol. 2003 Aug;49(2):276-80.

PMID:
12894077
31.

Lichen planus and cicatrizing conjunctivitis: characterization of five cases.

Thorne JE, Jabs DA, Nikolskaia OV, Mimouni D, Anhalt GJ, Nousari HC.

Am J Ophthalmol. 2003 Aug;136(2):239-43.

PMID:
12888044
32.

CD8+ T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus, and solitary Castleman's disease.

Hoffman MA, Qiao X, Anhalt GJ.

N Engl J Med. 2003 Jul 24;349(4):407-8. No abstract available.

PMID:
12878753
33.

Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris.

Nousari CH, Brodsky R, Anhalt GJ.

J Am Acad Dermatol. 2003 Jul;49(1):148-50. No abstract available.

PMID:
12833031
34.

Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil.

Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC.

Arch Dermatol. 2003 Jun;139(6):739-42.

PMID:
12810504
35.

Infliximab for peristomal pyoderma gangrenosum.

Mimouni D, Anhalt GJ, Kouba DJ, Nousari HC.

Br J Dermatol. 2003 Apr;148(4):813-6.

PMID:
12752145
36.

Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus.

Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, Ha E, Anhalt GJ, Provost TT, Nousari CH.

Arch Dermatol. 2003 Jan;139(1):45-9.

PMID:
12533163
37.

Paraneoplastic pemphigus in children and adolescents.

Mimouni D, Anhalt GJ, Lazarova Z, Aho S, Kazerounian S, Kouba DJ, Mascaro JM Jr, Nousari HC.

Br J Dermatol. 2002 Oct;147(4):725-32.

PMID:
12366419
38.

Bullous diseases in the elderly.

Mutasim DF, Anhalt GJ.

Clin Geriatr Med. 2002 Feb;18(1):43-58. Review.

PMID:
11913738
39.

The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators.

Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, Fine JD, Foster CS, Ghohestani R, Hashimoto T, Hoang-Xuan T, Kirtschig G, Korman NJ, Lightman S, Lozada-Nur F, Marinkovich MP, Mondino BJ, Prost-Squarcioni C, Rogers RS 3rd, Setterfield JF, West DP, Wojnarowska F, Woodley DT, Yancey KB, Zillikens D, Zone JJ.

Arch Dermatol. 2002 Mar;138(3):370-9. Review.

PMID:
11902988
40.

Chronic idiopathic acrocyanosis.

Nousari HC, Kimyai-Asadi A, Anhalt GJ.

J Am Acad Dermatol. 2001 Dec;45(6 Suppl):S207-8.

PMID:
11712060
41.

Paraneoplastic pemphigus: the role of tumours and drugs.

Anhalt GJ.

Br J Dermatol. 2001 Jun;144(6):1102-4. No abstract available.

PMID:
11422027
42.

Nonendemic pemphigus foliaceus presenting as fatal bullous exfoliative erythroderma.

Nousari HC, Moresi M, Klapper M, Anhalt GJ.

Cutis. 2001 Mar;67(3):251-2.

PMID:
11270302
43.

Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic pemphigus.

Ohyama M, Amagai M, Hashimoto T, Nousari HC, Anhalt GJ, Nishikawa T.

J Am Acad Dermatol. 2001 Apr;44(4):593-8.

PMID:
11260531
44.

Paraneoplastic pemphigus without antidesmoglein 3 or antidesmoglein 1 autoantibodies.

Inaoki M, Kodera M, Fujimoto A, Nousari HC, Anhalt GJ, Takehara K.

Br J Dermatol. 2001 Mar;144(3):610-3.

PMID:
11260026
45.

Prospects for autoimmune disease: Research advances in pemphigus.

Anhalt GJ, Diaz LA.

JAMA. 2001 Feb 7;285(5):652-4.

PMID:
11176877
46.

Esophageal lichen planus: case report and review of the literature.

Abraham SC, Ravich WJ, Anhalt GJ, Yardley JH, Wu TT.

Am J Surg Pathol. 2000 Dec;24(12):1678-82. Review.

PMID:
11117791
47.

Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent.

Nousari HC, Anhalt GJ.

Arch Dermatol. 2000 Oct;136(10):1204-5. No abstract available.

PMID:
11030765
48.

Mucous membrane pemphigoid presenting with isolated esophageal involvement: a case report.

Sallout H, Anhalt GJ, Al-Kawas FH.

Gastrointest Endosc. 2000 Sep;52(3):429-33. No abstract available.

PMID:
10968869
49.

Paraneoplastic pemphigus caused by an epithelioid leiomyosarcoma and associated with fatal respiratory failure.

van der Waal RI, Pas HH, Nousari HC, Schulten EA, Jonkman MF, Nieboer C, Stoof TJ, Starink TM, Anhalt GJ.

Oral Oncol. 2000 Jul;36(4):390-3.

PMID:
10899680
50.

Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading?

Bowen GM, Peters NT, Fivenson DP, Su LD, Nousari HC, Anhalt GJ, Cooper KD, Stevens SR.

Arch Dermatol. 2000 May;136(5):652-6.

PMID:
10815859

Supplemental Content

Loading ...
Support Center